IGC Pharma Inc - Company Profile
Powered by 
All the sales intelligence you need on IGC Pharma Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how IGC Pharma Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with IGC Pharma Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
IGC Pharma Inc (IGC), formerly India Globalization Capital Inc, is a pharmaceutical company with specialization in development of treatments related to Alzheimer’s disease.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
IGC is focused on developing treatments for Alzheimer's disease through a robust pipeline of drug candidates targeting different aspects of the disease. The company's R&D initiatives are primarily focused on the Life Sciences segment, with significant investments in advancing its product pipeline. The company is developing innovative mechanisms to address key pathological features like amyloid plaques and tau protein aggregation. Additionally, IGC is expanding into metabolic disorders, leveraging AI to identify promising therapeutic candidates. The company is also utilizing AI to develop early detection models, optimize clinical trials, and explore new applications for its drugs. IGC has been progressing Phase 2 trials on IGC-AD1 and conducting pre-clinical studies on TGR-63, which are key drivers of the increase in R&D expenses. The company is also actively pursuing intellectual property in the combination therapy space, particularly in the phytocannabinoid-based healthcare industry. As of June 2025, the company had filed 31 patents and twelve patents have been issued. The company has a major technology alliance with the Jawaharlal Nehru Centre for Advanced Scientific Research in India for the development of TGR-63. In FY2025, the company spent US$3.6 million on its R&D activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer